Log In
Print
BCIQ
Print
Print this Print this
 

Intermezzo, zolpidem

  Manage Alerts
Collapse Summary General Information
Company Paratek Pharmaceuticals Inc.
DescriptionLow-dose sublingual formulation of zolpidem
Molecular Target GABA A receptor
Mechanism of ActionGABA A receptor modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia; Treat insomnia when a middle of the night awakening is followed by difficulty returning to sleep
Regulatory Designation

Partner

Purdue Pharma L.P.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$553.3M

$100.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today